113136-89-3

Basic information

• Product Name: Cyclopropanecarboxylic acid, 1-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]-
• CAS NO: 113136-89-3
• Molecular Formula: C12H10F3NO3
• Molecular Weight: 273.212
• Mol File: 113136-89-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Cyclopropanecarboxylic acid, 1-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclopropanecarboxylic acid, 1-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]-(113136-89-3)
• EPA Substance Registry System: Cyclopropanecarboxylic acid, 1-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]-(113136-89-3)

Safety Data

• Hazardous Substances Data: 113136-89-3(Hazardous Substances Data)

Upstream product

• 6914-71-2 dimethyl 1,1-cyclopropanedicarboxylate 
• 455-14-1 4-trifluoromethylphenylamine 
• 598-10-7 cyclopropane-1,1-dicarboxylic acid 
• 40258-99-9 1-(chlorocarbonyl)cyclopropane-1-carboxylic acid 

Downstream Products

• 1584219-79-3 N-(4-((2-((3-((methylsulfonyl)methyl)phenyl)amino)pyrimidin-4-yl)oxy)phenyl)-N'-(4-(trifluoromethyl)phenyl)cyclopropane-1,1-dicarboxamide 

Relevant articles and documents

Synthesis and anti-tumor activity of [1,4] dioxino [2,3-f] quinazoline derivatives as dual inhibitors of c-Met and VEGFR-2

Both c-Met and VEGFR-2 were important targets for cancer therapies. In order to develop reversible and non-covalent c-Met and VEGFR-2 dual inhibitors, a series of [1,4]dioxino[2,3-f]quinazoline derivatives were designed and synthesized. The enzyme assay demonstrated that most target compounds had inhibition potency on both c-Met and VEGFR-2 with IC50 values in nanomolar range especially compounds 7m and 7k. Based on further cell proliferation assay in vitro, compound 7k showed significantly anti-tumor activity in vivo on a hepatocellular carcinoma (MHCC97H cells) xenograft mouse model. We docked the compound 7m with c-Met and VEGFR-2 kinases, and interpreted the SAR of these analogues. All results indicated that the target compounds were dual inhibitors of c-Met and VEGFR-2 kinases that held promising potential in cancer therapy.

Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate

A series of novel hybrid structure derivatives, containing both LEE011 and Cabozantinib pharmacophore, were designed, synthesized and evaluated. Surprisingly, a compound 4d was discovered that highly exhibited effective and selective activity of CDK9 inhi

SUBSTITUTED PYRIMIDINYL AND PYRIDINYL-PYRROLOPYRIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS

The present invention relates to substituted pyrimidinyl- and pyridinylpyrrolopyridinone compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular RET family kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions containing these compounds.